Daewoong Pharmaceutical, “It was not a criticism about serious errors related to Nabota”
In regards to the news about the FDA’s onsite inspection for ‘Nabora,’ Daewoong Pharmaceutical(CEO Jong-Wook Lee) announced on the 24th “The Daewoong Pharmaceutical’s Form 483 revealed at the FDA’s website is a document that is commonly issued about the status of manufacturer. Unlike it was menti...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
